Antibiotic management in cystic fibrosis;Mucovisciscidose. Prise en charge antibiotique

Presse Medicale

Volumn 26, Issue 15, 1997, Pages 727-732

  Le Bourgeois, M ^a,b   Gerardin M ^a   Munck, A ^a   Navarro, J ^a  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZTREONAM; CEFIXIME; CEFTAZIDIME; CIPROFLOXACIN; CLAVULANIC ACID; CLOXACILLIN; COTRIMOXAZOLE; FOSFOMYCIN; FUSIDATE SODIUM; FUSIDIC ACID; IMIPENEM; OXACILLIN; PIPERACILLIN; PRISTINAMYCIN; RIFAMPICIN; SULFAMETHOXAZOLE; TAZOBACTAM; TEICOPLANIN; TICARCILLIN; TOBRAMYCIN; TOBRAMYCIN SULFATE; TRIMETHOPRIM; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT;

BURKHOLDERIA CEPACIA; CYSTIC FIBROSIS; HAEMOPHILUS INFLUENZAE; HUMAN; OPPORTUNISTIC INFECTION; PATIENT CARE; PSEUDOMONAS AERUGINOSA; SHORT SURVEY; SPUTUM; STAPHYLOCOCCUS AUREUS; BACTERIAL INFECTION; BRONCHUS DISEASE; MICROBIOLOGY; REVIEW;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BRONCHIAL DISEASES; CYSTIC FIBROSIS; HUMANS;

EID: 0031551040     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (29)

1. Szaff M, Hoiby N, Flensborg EW. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr Stand 1983 ; 72:651-7.
2. Beardsmore CS, Thompson JR, Williams A et al. Pulmonary function in infants with cystic fibrosis, the effect of antibiotic treatment. Arch Dis Child 1994 ; 71:133-7.
3. Armstrong DS, Grimwood R, Carzino R, Carlin JB, Olinsky A, Phelan PD. Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. Br Med J 1995 ; 310:1571-2.
4. Balough K, MacCubbin M, Weinbereger M, The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Pediatr Pulmonol 1995 ; 2:63-70.
5. Konstan MW, Hilliard KA, Norvell TM, Berger M. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med 1994 ; 150:448-54.
6. Davis PB, Drumm M, Konstan MW. Cystic fibrosis. State of the art. Am J Respir Crit Care Med 1996 ; 154:1229-56.
7. May T, Shinabarger D, Maharaj R et al. Alginate synthesis by Pseudomonas aeruginosa a key pathogenic factor in chronic pulmonary infections of cystic fibrosis patients. Clin Microbiol Rev 1991 ; 4:194-206.
8. Bingen E. Données bactériologiques. In: La mucoviscidose, Navarro J, Bellon G eds. Editions Espaces 34, Montpellier, 1996:57-78.
9. Observatoire National de la mucoviscidose en France. Epidemiology of Cystic fibrosis in France. 9th Annual Cystic Fibrosis Conference, Dallas, Abstract, Pediatr Pulmonol 1995 ; suppl 12:287.
10. Bingen E, Denamur E, Picard B et al. Molecular epidemiological analysis of Pseudomonas aeruginosa strains causing failure of antibiotic therapy in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 1992 ; 11:432-7.
11. Dournes J, Marty N, Chabanon ? Pseudomonas aeruginosa : ses marqueurs épidémiologiques. Lettre de l'infectiologue 1994 ; 9:432-9.
12. Gilligan PH. Microbiology of airway disease in patients with cystic fibrosis. Clin Microbiol Rev 1991 ; 4:35-51.
13. De Groot R, Smith A. Antibiotics pharmacokinetics in cystic fibrosis: differences and clinical significance. Clin Pharmacokin 1987 ; 13:228-53.
14. Grenier B, Autret E, Marchand S. Kinetic parameters of amikacin in cystic fibrosis children. Infection 1987 ; 15:295-8.
15. Stutman H for the Keflex study group; To Keflex or not Keflex: long term antibiotics in CF. 9th Annual cystic Fibrosis conference, Brussels, 1995, Abstract S12-2. Pediatr Pulmonol 1995 Suppl. 12.
16. Weaver LT. Prognosis in cystic fibrosis treated with continuous fluoxacillin from the neonatal period. Arch Dis Child 1979 ; 70:84-9.
17. Foucaud P, Bingen E, Lambert-Zechovsky N, Navarro J. Infection à pyocyanique dans la mucoviscidose. Stratégies thérapeutiques. Presse Med 1990 ; 19:983-5.
18. Verpooten GA, Giuliano RA Verbist L et al. Once-daily dosing decreases renal accumulation of gentamycin and netilmicin. Clin Pharmacol Ther 1989 ; 45:22-7.
19. Vasquez C, Munico M, Corera M et al. Early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Acta Pediatrica 1993 ; 82:308-9.
20. Bellon G, Gilly R, Brun O. Manifestations respiratoires et prise en charge. In: La mucoviscidose, Navarro J, Bellon G eds. Editions Espaces 34, Montpellier 1996:153-97.
21. Borish L, Tamir R, Rosenwasser U. Intravenous desensitization to beta-lactam antibiotics J Allergy Clin Immunol 1987 ; 80:14-19.
22. Silly C, Lenoir G, Navarro J. Thérapeutiques inhalées au cours de la mucoviscidose. Journées Parisiennes de pédiatrie. Flammarion/Médecine-Science 1992: 87-93.
23. Hodson ME, Penketh ARL, Batten JC. Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Lancet 1981 ; ii:1137-9.
24. Valerius NH, Koch C, Hoiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 1991 ; 338:725-6.
25. Stephens D, Garey N, Isles A et al. Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis. Pediatr Infect Dis 1983 ; 2:209-11.
26. Schaad UB, Wedgwood-Krucko J, Suter S et al. Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis. J Pediatr 1987 ; 11:599-605.
27. Mac Lusky IB, Cold R, Corey M, Levison H. Long term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Pulmonol 1989 ; 7:42-8.
28. Touw DJ, Brimicombe RW, Hodson ME, Heijerman HGM, Bakker W. Inhalation of antibiotics in cystic fibrosis. Eur Respir J 1995 ; 8:1594-1604.
29. Ramsey BW, Dorkin HL, Eisenberg JD et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993 ; 328:1740-6.